Pictet Asset Management Holding SA Sells 72,387 Shares of Abivax SA Sponsored ADR $ABVX

Key Points

• Pictet Asset Management cut its Abivax stake by 36.8%, selling 72,387 shares and leaving it with 124,449 shares worth about $16.78 million (≈0.16% of the company); overall institutional ownership is roughly 47.9%.
• Analyst sentiment is generally positive with a consensus rating of "Moderate Buy" and an average price target of $137.15, though views vary from buy/outperform (Jefferies $160, BTIG $150) to a sell from Weiss Ratings.
• Shares traded around $117.61 with a market cap of $9.33 billion; the company is still unprofitable (last quarter EPS -$1.20, consensus -3.84 EPS for the year) and has a 12‑month range of $5.59–$148.83.

Pictet Asset Management Holding SA cut its position in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) by 36.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,449 shares of the company's stock after selling 72,387 shares during the quarter. Pictet Asset Management Holding SA owned about 0.16% of Abivax worth $16,783,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABVX. EverSource Wealth Advisors LLC grew its position in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after acquiring an additional 369 shares during the period. First Horizon Corp acquired a new stake in Abivax in the 3rd quarter valued at about $36,000. Bank of America Corp DE grew its holdings in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new position in Abivax during the third quarter worth approximately $52,000. Finally, WPG Advisers LLC boosted its stake in shares of Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company's stock worth $61,000 after acquiring an additional 253 shares during the period. 47.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Jefferies Financial Group assumed coverage on Abivax in a report on Monday, March 16th. They set a "buy" rating and a $160.00 price target for the company. BTIG Research restated a "buy" rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Abivax in a research note on Monday, April 20th. Wedbush initiated coverage on Abivax in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $110.00 price target for the company. Finally, Oddo Bhf reissued an "outperform" rating on shares of Abivax in a research report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $137.15.

Abivax Trading Up 0.2%

Shares of NASDAQ ABVX opened at $117.61 on Friday. The company has a market cap of $9.33 billion, a price-to-earnings ratio of -21.90 and a beta of 0.84. Abivax SA Sponsored ADR has a 12 month low of $5.59 and a 12 month high of $148.83. The stock has a 50-day moving average price of $117.02 and a two-hundred day moving average price of $116.30.

Abivax (NASDAQ:ABVX - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The firm had revenue of $0.52 million for the quarter. On average, sell-side analysts predict that Abivax SA Sponsored ADR will post -3.84 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.